Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Herald Grenada.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on May 8, 2025
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the …
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
GlobeNewswire
·
May 8, 2025
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted …
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as Senior Vice President, Clinical Development Reported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 …
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 8, 2025
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
GlobeNewswire
·
May 8, 2025
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and …
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal …
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025 …
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …
Senseonics Holdings, Inc. Reports First Quarter Financial Results
GlobeNewswire
·
May 8, 2025
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 …
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
GlobeNewswire
·
May 8, 2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives …
Cytek Biosciences Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …
Treace Medical Concepts Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
May 8, 2025
Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …
TELA Bio Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended …
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
GlobeNewswire
·
May 8, 2025
● Q1 Revenue of $11.5 million; a 13% increase year-over-year ● Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ● Q1 Thyroid test volume up 16% year-over-year to record levels ● Q1 Thyroid revenue of $8.0M; up …
The Joint Corp. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
- Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience - SCOTTSDALE, Ariz., May 08, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, …
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …
Ceribell Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial …
CVRx Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 8, 2025
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …
SIGA Reports Financial Results for Three Months Ended March 31, 2025
GlobeNewswire
·
May 8, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …